Most organisations do not bring in commercial expertise because they suddenly need procurement support. They do it because the financial consequences of supplier decisions become too significant to manage informally. As organisations grow, complexity increases — supplier relationships multiply, technology spend expands, and contracts signed years earlier begin to approach renewal. What was once manageable through judgement alone becomes a portfolio of commercial commitments that requires structured oversight.
The warning signs are usually consistent. A strategic supplier proposes a price increase and there is limited market context to challenge it. Software and technology contracts renew with costs increasing faster than value delivered. Commercial decisions become distributed across finance, operations, and technology teams without a single point of coordination or accountability.
In investor-backed businesses, the pressure presents differently. A funding round, acquisition, or exit brings scrutiny to areas that have not previously required detailed justification — supplier dependency, contract assignability, long-term liabilities, and commercial exposure beneath reported performance. What appears manageable operationally can become material under external review.
This is where I become involved. I work with founders, CFOs, leadership teams, and investors when commercial decisions have reached a level of significance that benefits from experienced support — not as a replacement for internal leadership, but as an extension of it. The objective is improved commercial outcomes: reducing unnecessary cost, strengthening supplier arrangements, improving commercial structure, and ensuring organisations are prepared for the scrutiny and opportunity that comes with growth, investment, or transaction. Every engagement is led personally.
When I join an organisation, the objective is not to advise from the sidelines. It is to take ownership of the commercial decisions that are already in motion and improve their outcomes immediately.
This typically means stepping into live supplier relationships, upcoming renewals, ongoing procurement activity, and existing contract portfolios — and bringing structure, leverage and commercial discipline to decisions that are already affecting cost, risk and delivery.
The value comes from being able to operate across the full commercial lifecycle without transition time: from understanding spend and supplier dependency, through structuring requirements, shaping market engagement, leading negotiations, and into contract execution and ongoing supplier performance management.
I work as an embedded commercial lead within the leadership team, focused on outcomes rather than activity — resetting commercial position where it has drifted, strengthening upcoming negotiations, and putting in place the structures that allow commercial decisions to scale with the business.
Investment decisions increasingly depend on understanding what sits beneath the headline financials. Revenue forecasts, contracted pipelines and secured deals often look stable at surface level, but the underlying commercial structure tells a different story.
The strength of frameworks, the reality of direct awards, the durability of renewal-based revenue, and the concentration of key suppliers all materially affect valuation, risk and post-deal performance.
I work with private equity firms, venture investors and corporate development teams at key transaction points — typically before data room opening, during commercial due diligence, prior to exit, or ahead of follow-on investment rounds where assumptions about growth and revenue quality need validation.
The output is a clearer view of commercial reality — not just whether the numbers work, but whether they will hold under ownership, competition and regulatory change.
Across sectors — from healthcare and financial services to logistics, construction, professional services and public sector organisations — the commercial dynamics of technology procurement are increasingly consistent. The pricing models may differ, but the underlying structure is the same: subscription-based commitments, consumption-driven cost exposure, and renewal mechanisms that steadily shift leverage toward the vendor over time.
Enterprise technology suppliers operate within this model every day. Most organisations do not. As a result, commercial exposure often accumulates gradually rather than visibly — through auto-renewals agreed years earlier, consumption growth that outpaces forecasting, contract terms that were never stress-tested at scale, and pricing models that become more complex as platforms expand across the business.
This work covers major enterprise platforms including Microsoft EA, Azure and AI services, Salesforce, SAP, ServiceNow and Databricks — alongside broader cloud ecosystems and wider SaaS portfolios where overlap, duplication and uncontrolled expansion are common as organisations scale. Engagement typically begins ahead of renewals, during contract consolidation programmes, or when organisations are reviewing spend as part of cost optimisation, transformation or investment readiness activity.
The objective is not procurement activity in isolation. It is establishing a stronger commercial position across the technology estate — improving pricing outcomes, reducing avoidable exposure, and ensuring future contracts are structured with a clearer balance of risk and control.
Winning work in UK public sector markets is not determined at the point of tender submission. It is determined much earlier — in how well a supplier understands the structure of demand, the dynamics of frameworks, and the commercial logic that sits behind procurement decisions.
I work with technology and medtech organisations looking to establish or scale their position in UK public sector markets, as well as investors assessing the realism and durability of public sector revenue within portfolio companies.
For medtech manufacturers and international suppliers, the challenge is rarely product capability. It is understanding how to position that capability within a system that is highly structured, highly regulated, and commercially distinct from most global healthcare markets.
The objective is to shorten the path to credible market participation — ensuring organisations enter with a clear understanding of where they can win, how revenue will be secured, and what it will take to sustain it.
These outcomes reflect work across supplier estates, technology portfolios, regulated organisations and transaction environments where commercial decisions have a direct impact on cost, risk and enterprise value.
£24.5 million in contract savings delivered across a central government technology portfolio through structured renegotiation of enterprise software, infrastructure and managed service agreements, resetting commercial position across multiple suppliers rather than individual contracts.
A long-term SaaS platform agreement at a major financial regulator restructured to reduce annual cost escalation by approximately 50%, delivering £2.5 million in savings while expanding commercial scope into data and AI capability.
Commercial oversight of a live acquisition and divestment programme within a healthcare services business, where early termination and transition negotiations recovered £2.87 million and maintained continuity across more than 150 operational sites without service disruption.
A four-year communications and mobile contract negotiated with £1.6 million in savings, including structured protection against inflation-driven price increases embedded into early contract years.
£3.1 million in recurring commercial income created for a local authority through structured partnership models applied to council-owned assets, establishing commercial frameworks where none previously existed.
Across these engagements, the common outcome is consistent: improved commercial position, reduced unnecessary exposure, and stronger long-term control over cost, contract structure and supplier performance.
Selected engagements in detail →If the commercial challenge you are facing requires senior expertise — get in touch.
Contact